Biofrontera Inc. (NASDAQ:BFRI) Sees Significant Decline in Short Interest

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 32,907 shares, a decrease of 46.1% from the July 30th total of 61,079 shares. Based on an average trading volume of 464,283 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Zacks Research upgraded shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen raised shares of Biofrontera to a “hold” rating in a report on Saturday, July 18th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Biofrontera currently has a consensus rating of “Hold”.

Biofrontera Price Performance

Shares of BFRI traded up $0.10 during mid-day trading on Friday, hitting $1.59. 807,575 shares of the company traded hands, compared to its average volume of 551,162. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $23.61 million, a price-to-earnings ratio of -3.53 and a beta of 0.78. The business has a 50-day moving average of $1.19 and a 200 day moving average of $1.02. Biofrontera has a one year low of $0.55 and a one year high of $1.61.

Biofrontera (NASDAQ:BFRI) last released its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $9.50 million. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. As a group, equities analysts expect that Biofrontera will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Biofrontera stock. Geode Capital Management LLC raised its position in Biofrontera Inc. (NASDAQ:BFRI) by 54.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the period. Geode Capital Management LLC owned approximately 0.56% of Biofrontera worth $37,000 as of its most recent filing with the SEC. Institutional investors own 10.08% of the company’s stock.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.